^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PTPN11 mutation + NPM1 mutation

    i
    Other names: PTPN11, Protein Tyrosine Phosphatase Non-Receptor Type 11, Tyrosine-Protein Phosphatase Non-Receptor Type 11, Protein-Tyrosine Phosphatase 1D, Protein-Tyrosine Phosphatase 2C, SH-PTP2, SH-PTP3, PTP-1D, PTP2C, Protein Tyrosine Phosphatase Non-Receptor Type 11, Noonan Syndrome 1, METCDS, PTP-2C, SHPTP2, BPTP3, SHP-2, JMML, SHP2, Shp2, CFC, NS1, Nucleophosmin (Nucleolar Phosphoprotein B23, Numatrin), Testicular Tissue Protein Li 128, Nucleolar Protein NO38, Numatrin, NPM1, Nucleophosmin 1, Nucleoph
    Entrez ID:
    4869; 5781
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    Associations

    News

    Trials
    3years
    [VIRTUAL] The Clinicopathological Features of DNMT3A R882 Mutant Myeloid Neoplasms (USCAP 2021)
    DNMT3A R882 mutant MNs show unique clinicopathological characteristics. They are more associated with AML and high-grade MDS at presentation in comparison to DNMT3A non-R882 mutant MNs. A clinical study with a larger cohort is needed to further address the diagnostic and prognostic utilities of DNMT3A R882 mutations.
    Clinical
    |
    TP53 (Tumor protein P53) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    |
    TP53 mutation • NPM1 mutation • DNMT3A mutation • PTPN11 mutation • U2AF1 mutation • DNMT3A R882 • PTPN11 mutation + NPM1 mutation